CAMBRIDGE, Mass, October 2, 2023 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company, today announced that it will participate in the following investor conferences:
- Chardan’s 7th Annual Genetic Medicines Conference, taking place October 2-3, 2023, in NY
- Oppenheimer’s Private Company Symposium, taking place October 11, 2023, in NY
- 3rd Annual Needham Private Biotech Company Virtual 1×1 Forum, taking place October 17-18, 2023
About Myeloid Therapeutics
Myeloid Therapeutics is a clinical stage oncology company developing novel therapies for cancer. Integrating the fields of mRNA-based therapeutics, immunology, and cancer biology, the Company’s proprietary platform provides clinical solutions for patients with solid tumors.